Forbius

NEW YORK: Bristol Myers Squibb has successfully completed its transaction to acquire Forbius for their TGF-beta program, including its lead investigational asset AVID200, currently in Phase 1 for oncology and fibrosis. “We are pleased to complete the transaction with Forbius…